- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
November 11, 2024Tommy Du Honored With 2024 Sheila Sonenshine Associate Pro Bono Award
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Oxbryta (Voxelotor) Sickle Cell Medication Recall
You must read the following notice before sending an e-mail message to Robins Kaplan LLP.
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
Robins Kaplan LLP is Investigating Safety Concerns of Sickle Cell Disease Medication
If you have experienced severe complications after taking Pfizer’s Oxbryta sickle cell medication, please call us at 1.800.553.9910 or complete our online contact form for a free claim evaluation.
Pharmaceutical giant Pfizer is voluntarily recalling Oxbryta from the market and is ceasing distribution because recent data indicates a diminishing benefit of Oxbryta due to safety concerns. The drugmaker states in part that the “decision is based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population.”1
The U.S. Food and Drug Administration (FDA) notes side effects of Oxbryta in certain studies include more deaths in the treatment group compared to the placebo group, along with an increased rate of vaso-occlusive crisis (VOC) in patients, which is very painful and occurs when sickle-shaped red blood cells restrict blood flow and oxygen delivery to tissues.2
Who Is Affected by the Oxbryta Recall?
The FDA has advised health care professionals to discontinue prescribing Oxbryta. Initially, in 2019, the sickle cell disease (SCD) medication received accelerated approval for patients 12 years and older. Two years later, the FDA extended its approval to include patients ages 4 to 11.
Many Oxbryta users experienced vaso-occlusive events and fatal complications, including:
- Increased pain severity associated with a pain crisis (or sickle crisis)
- Disabling pain crises requiring hospitalization
- Longer hospitalizations for acute chest pain
- Stroke
- Splenic pooling and spleen removal
Contact Robins Kaplan for an Evaluation of Your Potential Case
If you have been prescribed Oxbryta and experienced severe health issues, the attorneys at Robins Kaplan may be able to help. Our experienced lawyers can help assess your case and provide crucial support while advocating for your rights.
To discuss your possible case with our team, please call 1.800.553.9910 or complete our online contact form above.
RELATED PROFESSIONALS
Julie A.K. Reynolds
Associate
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.